Impact of Epstein-Barr virus and CD lymphocytes on the prognosis of patients with advanced nasopharyngeal carcinoma

Table 4 COX analysis of risk factors for progression

Variables	Class	Crude		Adjusted in model 1		Adjusted in model 2
Variables	Class	HR(95%CL)	p	HR (95%CL)	p	HR(95%CL)	p
Age	≥ 60 vs. <60	2.189 (0.988,4.852)	0.054	1.739 (0.772,3.918)	0.182
T staging	T3 vs..T1-2	3.642 (1.147,11.565)	0.028	4.099 (1.191,14.101)	0.025	4.457 (1.318,15.073)	0.016
T staging	T4 vs. T1-2	7.368 (2.311,23.489)	< 0.001	7.522 (2.230, 25.377)	0.001	7.906 (2.359,26.491)	< 0.001
Extra-lymph node metastasis	No vs. Yes	0.379 (0.142,1.009)	0.052	0.576 (0.202,1.643)	0.302
B cells (%)	< 12 vs. ≥ 12	2.253 (1.008,5.035)	0.048	2.503 (1.062,5.899)	0.036	2.800 (1.226,6.399)	0.015
EB DNA	Positive vs. Negative	3.513 (1.592,7.753)	0.002	2.739 (1.222,6.135)	0.014	2.678 (1.202,5.970)	0.016

Notation: Multivariate COX model included variables with p < 0.05 in the comparison results of progression-free survival curves as independent variables. On the basis of model 1, the independent variable with p > 0.05 was eliminated

ISSN: 1750-9378